SEC Form 4 · accession 0001209191-17-056550
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher B Prentiss
Officer — Chief Accounting Officer
Period of report
Oct 6, 2017
Accepted (ET)
Oct 10, 2017 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 6, 2017 | A | 2,500 | $0.00 | A | 12,405 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $23.11 | Oct 6, 2017 | A | 15,000 | A | — | Oct 5, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Represents the grant of restricted stock units that vest 1/4th on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021.
- F2The shares subject to the option vest and become exercisable in equal monthly installments on the 1st of every month over four years with the first vesting on October 1, 2017.